...the company. Formerly CEO of MirImmune Inc. , Eliseev joined RXi in January when it acquired MirImmune...

...RXi received an exclusive option to acquire immunotherapy company MirImmune. If exercised, MirImmune would receive a...
...Aug. 5. RXi may exercise the option before April 5, 2017. Last year, RXi granted MirImmune...
...technologies sd-rxRNA and rxRNAori to develop cell-based cancer immunotherapies involving ex vivo modification of cells. MirImmune...

...RXi granted MirImmune an exclusive license to use RNAi delivering technology, sd-rxRNA and rxRNAori, to develop...
...to develop cell-based cancer immunotherapies. MirImmune is responsible for R&D, manufacturing, regulatory approval and commercialization. MirImmune...
...income and single-digit royalties. RXi has an option to acquire a double-digit equity stake in MirImmune...